Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.36 |
| ▸ | PDE1A | P54750 | 3/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.32 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723512 | 0.83 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL14723281 | 0.83 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL14722690 | 0.81 | RXRA (0.41) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL3868044 | 0.80 | RXRA (0.43) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL27151032 | 0.76 | RXRA (0.46) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL17442631 | 0.75 | RXRA (0.48) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL7132596 | 0.75 | RXRA (0.55) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL28627588 | 0.74 | RXRA (0.44) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30932767 | 0.73 | RXRA (0.48) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL3640296 | 0.72 | RXRA (0.64) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | RXRA 1879/4885RXRB 1556/4885RXRG 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.